Not a good buy right now: the stock is extended after a sharp regular-session pop (+8.52%) but is fading post-market (-4.50%), suggesting weak follow-through.
Trend quality is poor (SMA_200 > SMA_20 > SMA_5). Even with a positive MACD histogram, this looks more like a short-term bounce inside a broader downtrend.
With earnings on 2026-02-19 (pre-market) and very weak recent revenue/earnings trends, the near-term setup is event-risk without a strong technical base.
Intellectia Proprietary Trading Signals: no AI Stock Picker signal and no SwingMax entry; no high-conviction systematic buy trigger today.
Technical Analysis
Price action: strong intraday gain but post-market reversal; current post-market price 1.06 sits below the pivot (1.089), which tilts near-term bias bearish unless it reclaims that level.
MACD: histogram 0.0036 and expanding > 0 = short-term momentum improving, but not enough to override bearish MA structure.
RSI(6): 70.206 (near overbought). After a spike, this increases the odds of a pullback/chop rather than a clean continuation.
Levels: Resistance R1 1.188 then R2 1.25; Support S1 0.99 then S2 0.928. A drop below 0.99 would be a clear technical deterioration.
Pattern-based projection (similar candlesticks): indicates modest positive drift (next day ~0.85%, next week ~2.79%, next month ~5.34%), but the current tape (fade after spike) is not an attractive “buy-now” entry.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Options look extremely thin/illiquid (key fields blank); the 0.0 put-call ratios are more consistent with minimal recorded put activity than a reliable bullish sentiment signal.
Historical volatility is very high (71.65), implying large price swings; without clear open interest/volume confirmation, options sentiment is low-confidence.
Technical Summary
Sell
6
Buy
8
Positive Catalysts
Short-term momentum improved (MACD histogram positive and expanding), which can support brief continuation bounces.
Upcoming earnings on 2026-02-19 (pre-market) can act as a volatility catalyst if results/surprises are positive.
Gross margin improved in 2025/Q3 (49.68%, +23.86% YoY), showing some efficiency improvement despite revenue weakness.
Neutral/Negative Catalysts
near overbought after a pop increases pullback risk at current levels.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 312,000, down -82.07% YoY (major top-line contraction).
Net income: 3,874,000, down -150.77% YoY (profitability deteriorated sharply vs prior year period).
EPS: 0.44, down -133.59% YoY.
Gross margin: 49.68%, up +23.86% YoY (margin improved, but it did not offset the revenue collapse).
Overall: the quarter shows shrinking scale with worsening bottom-line trend, which is not the profile of a strong “buy now” setup heading into the next earnings.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating trend or price target change data was provided, so Wall Street pro/con positioning cannot be verified from the dataset.
Practical takeaway: absent visible analyst upgrades/targets and with weak fundamentals, there is no clear institutional/coverage-driven support signal here.
Wall Street analysts forecast EVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is 2.5 USD with a low forecast of 2.5 USD and a high forecast of 2.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast EVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is 2.5 USD with a low forecast of 2.5 USD and a high forecast of 2.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.100
Low
2.5
Averages
2.5
High
2.5
Current: 1.100
Low
2.5
Averages
2.5
High
2.5
Alliance Global Partners
Scott Henry
Buy
downgrade
$6
AI Analysis
2025-06-06
Reason
Alliance Global Partners
Scott Henry
Price Target
$6
AI Analysis
2025-06-06
downgrade
Buy
Reason
Alliance Global Partners analyst Scott Henry lowered the firm's price target on Evogene to $3.50 from $6 and keeps a Buy rating on the shares, citing lower forecasts and potentially higher equity dilution after the company reported Q1 earnings that featured a revenue shortfall offset by cost cuts. The Lavie Bio sale should fortify the balance sheet, although at a lower price than expected, and Casterra castor seed revenue continues to trail the firm's forecasts, the analyst noted.
Lake Street
Ben Klieve
Buy
downgrade
$5
2025-05-22
Reason
Lake Street
Ben Klieve
Price Target
$5
2025-05-22
downgrade
Buy
Reason
Lake Street analyst Ben Klieve lowered the firm's price target on Evogene to $3.50 from $5 and keeps a Buy rating on the shares. Mixed Q1 results were highlighted by an extended cash runway via a Lavie Bio asset sale and strong year-over-year growth out of Casterra, the analyst tells investors. The number of potential catalysts is declining, but a major potential event of a follow on seed order and/or commercial castor oil agreement "represent the major potential events in 2025," the analyst says. The firm maintains a Buy rating on Evogene, but adds that "our conviction has been on the decline for several quarters."
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVGN
